[1]
Schoedel, PhD, K.A., Rolleri, PharmD, R.L., Faulknor, MD, CCFP, J.Y., Pixton, MS, G.C., Chen, PhD, N., Bass, PharmD, A., Sommerville, MD, K.W. and Sellers, MD, PhD, FRCPC, FACP, E. 2012. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users. Journal of Opioid Management. 8, 5 (Sep. 2012), 315–327. DOI:https://doi.org/10.5055/jom.2012.0131.